| |
Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera
- 作者:Mohamad Cherry (1) (5)
Mohamad Khawandanah (1) Zhizhuang Joe Zhao (2) Samer Srour (1) Howard Ozer (3) George Selby (1) Bassam Ghabache (1) Aref Al-Kali (4)
1. Hematology/Oncology ; Oklahoma University Health Sciences Center ; Oklahoma City ; OK ; USA 5. Stephenson Cancer Center ; University of Oklahoma Health Sciences Center ; 800 NE 10th street ; Oklahoma City ; OK ; 73102 ; USA 2. Pathology ; Oklahoma University Health Sciences Center ; Oklahoma City ; OK ; USA 3. Hematology/Oncology ; University of Illinois at Chicago ; Chicago ; IL ; USA 4. Hematology ; Mayo Clinic ; Rochester ; MN ; USA
- 刊名:Annals of Hematology
- 出版年:2015
- 出版时间:April 2015
- 年:2015
- 卷:94
- 期:4
- 页码:717-719
- 全文大小:245 KB
- 参考文献:1. Zhao, R, Xing, S, Li, Z (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280: pp. 22788-22792 CrossRef
2. Li, Z, Xu, M, Xing, S (2007) Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem 282: pp. 3428-3432 CrossRef 3. Xing, S, Wanting, TH, Zhao, W (2008) Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 111: pp. 5109-5117 CrossRef 4. Furqan, M, Mukhi, N, Lee, B, Liu, D (2013) Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res 1: pp. 5 CrossRef 5. Verstovsek, S, Mesa, RA, Gotlib, J (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366: pp. 799-807 CrossRef 6. Tefferi, A, Vardiman, JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22: pp. 14-22 CrossRef 7. A鈥橦ern, RP (2001) Sample size tables for exact single-stage phase II designs. Stat Med 20: pp. 859-866 CrossRef 8. Barosi, G, Birgegard, G, Finazzi, G (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 113: pp. 4829-4833 CrossRef 9. Verstovsek, S, Passamonti, F, Rambaldi, A (2014) A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 120: pp. 513-520 CrossRef
- 刊物类别:Medicine
- 刊物主题:Medicine & Public Health
Hematology Oncology
- 出版者:Springer Berlin / Heidelberg
- ISSN:1432-0584
| |
NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.
| |